New drug combo tested in battle against tough ovarian cancer
NCT ID NCT03026062
Summary
This study tested two different ways of giving immunotherapy drugs (durvalumab and tremelimumab) to women with recurrent ovarian, fallopian tube, or primary peritoneal cancer that had stopped responding to standard platinum-based chemotherapy. The goal was to see if giving the drugs together worked better than giving them one after the other at controlling the cancer. Researchers enrolled 100 participants to compare how long the cancer stayed under control and to monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.